Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Kramer

Showing results (111-120 of 117) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 117 results.
The Lancet. Rheumatology|January 22, 2024
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trialOliver Distler, Yannick Allanore, Christopher P Denton, et al.
Annals of the Rheumatic Diseases|April 18, 2020
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trialDinesh Khanna, Yannick Allanore, Christopher P Denton, et al.
Rheumatology (Oxford, England)|March 9, 2024
Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosisDinesh Khanna, Frank Kramer, Josef Höfler, et al.
Circulation. Heart Failure|October 21, 2016
Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection FractionJaved Butler, Carine E Hamo, James E Udelson, et al.
Medical Image Analysis|October 12, 2024
RFMiD: Retinal Image Analysis for multi-Disease Detection challengeSamiksha Pachade, Prasanna Porwal, Manesh Kokare, et al.
Neurological Research and Practice|March 6, 2024
Prospective study validating a multidimensional treatment decision score predicting the 24-month outcome in untreated patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis, the ProVal-MS studyAntonios Bayas, Ulrich Mansmann, Begum Irmak Ön, et al.
Therapeutic Advances in Neurological Disorders|November 24, 2025
External validation of a multiple sclerosis treatment decision score using data from the ProVal-MS cohort studyStefan Buchka, Alexander Hapfelmeier, Jan S Kirschke, et al.
Pageof 12

Showing results (111-120 of 117) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 117 results.
The Lancet. Rheumatology|January 22, 2024
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trialOliver Distler, Yannick Allanore, Christopher P Denton, et al.
Annals of the Rheumatic Diseases|April 18, 2020
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trialDinesh Khanna, Yannick Allanore, Christopher P Denton, et al.
Rheumatology (Oxford, England)|March 9, 2024
Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosisDinesh Khanna, Frank Kramer, Josef Höfler, et al.
Circulation. Heart Failure|October 21, 2016
Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection FractionJaved Butler, Carine E Hamo, James E Udelson, et al.
Medical Image Analysis|October 12, 2024
RFMiD: Retinal Image Analysis for multi-Disease Detection challengeSamiksha Pachade, Prasanna Porwal, Manesh Kokare, et al.
Neurological Research and Practice|March 6, 2024
Prospective study validating a multidimensional treatment decision score predicting the 24-month outcome in untreated patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis, the ProVal-MS studyAntonios Bayas, Ulrich Mansmann, Begum Irmak Ön, et al.
Therapeutic Advances in Neurological Disorders|November 24, 2025
External validation of a multiple sclerosis treatment decision score using data from the ProVal-MS cohort studyStefan Buchka, Alexander Hapfelmeier, Jan S Kirschke, et al.
Pageof 12